Company Description
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment.
The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Country | United States |
| IPO Date | Oct 4, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,779 |
| CEO | Dr. Helmy Eltoukhy Ph.D. |
Contact Details
Address: 3100 Hanover Street Palo Alto, California 94304 United States | |
| Phone | 855-698-8887 |
| Website | guardanthealth.com |
Stock Details
| Ticker Symbol | GH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576280 |
| CUSIP Number | 40131M109 |
| ISIN Number | US40131M1099 |
| Employer ID | 45-4139254 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-Chief Executive Officer and Chairman |
| Dr. AmirAli Talasaz Ph.D. | Co-Chief Executive Officer and Director |
| Michael Bell | Chief Financial Officer |
| John G. Saia | Chief Legal Officer and Corporate Secretary |
| Dr. Craig Eagle M.D. | Chief Medical Officer |
| Christopher Freeman | Chief Commercial Officer |
| Darya Chudova | Chief Technology Officer |
| Kumud Kalia | Chief Information Officer |
| Jennifer Higgins | Vice President of Public Affairs |
| Terilyn Juarez Monroe | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 144 | Filing |
| Feb 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | 8-K | Current Report |